Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report
(Date of earliest event reported): December 27, 2010
 
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-15281
76-0233274
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
2408 Timberloch Place, Suite B-7
The Woodlands, Texas  77380
(Address of principal
executive offices
and zip code)
 
(281) 719-3400
(Registrant’s telephone number, including area code)
  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[  ]           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 8.01  Other Events.
 
On December 27, 2010, Repros Therapeutics Inc. (the “Company”) issued a press release titled “Vaginal Delivery of Repros’® Proellex® Bypasses First Pass Liver Effects and Achieves Greater Signals of Efficacy at Significantly Lower Exposure.”

On December 28, 2010, the Company issued a press release titled “Reanalysis by Outside Statistician Shows Androxal® Provides Statistically Significant Improvement in Testosterone Levels in Men with Male Hormone Levels ≤ 250 ng/dL.”

Copies of such press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2 and are incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.
 
(d)  Exhibits.
                               
 
Exhibit
  
 
Number
 Description
     
99.1 
Press Release dated December 27, 2010

99.2 
Press Release dated December 28, 2010
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Repros Therapeutics Inc.  
       
Date:  December 28, 2010      
       
 
By:
/s/ Joseph S. Podolski  
    Joseph S. Podolski  
    President and Chief Executive Officer  
 
 
EXHIBIT INDEX
 
 
Exhibit
  
 
Number
 Description
     
99.1 
Press Release dated December 27, 2010

99.2 
Press Release dated December 28, 2010